Navigation Links
Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation

- Former Research Team Director and Key Strategy Architect to Build on

Foundation's Momentum In Pursuing Systemic Changes to Advance in

Parkinson's Disease Treatments -

NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced that Katie Hood, Deputy Chief Executive Officer and former Research Director, has been appointed Interim Chief Executive Officer. Ms. Hood, who joined the Foundation in September 2002, has played critical roles in shaping its strategy of intervening aggressively to close critical gaps in the process of moving potential treatments from the laboratory to Parkinson's patients, as well as in building a team of in-house research experts needed to implement that strategy.

Ms. Hood replaces CEO Sarah Orsay, who is leaving MJFF in order to devote more time to her three children.

MJFF Founder Michael J. Fox said, "The Michael J. Fox Foundation has grown enormously in our sophistication and in our capability to work with everyone from academic researchers to industry in plugging the many gaps in the process that keep promising science from advancing to effective, life-changing treatments for Parkinson's. Katie Hood has played a big part in that evolution, and we're confident that with her at the helm, we will not only maintain our momentum but will continue to build our reputation for not just throwing money at the problem, but truly taking a leadership role in helping identify and cultivate research breakthroughs."

Ms. Hood stated, "After five years working with management and staff at all levels of MJFF, as well as our scientific advisors, grantees, industry partners and donors, I am looking forward to working with Michael, our Board and our entire team to further advance the mission and strategy of a foundation that is increasingly setting the standard for effectiveness and best business practices."

As Interim Chief Executive Officer, Ms. Hood will provide day-to-day management and oversight of all Foundation activities and will specifically oversee fundraising, the Foundation's research team and communications, administration and financial management. Ms. Hood will report to the Board of Directors. Debi Brooks will continue to serve as co-founder with a focus on principal-gifts fundraising and outreach to key external audiences, reporting to the Board of Directors.

The Foundation stated that Ms. Hood will be a candidate to assume the CEO position on a permanent basis.

Prior to joining the Foundation, Ms. Hood was employed as a consultant at Bain & Company in New York City, doing work in the consumer products, financial services, and nonprofit sectors. She has also served as an analyst in the Credit Department of Goldman, Sachs & Co., and as a program coordinator with Duke University's Hart Leadership Program. Ms. Hood graduated from Harvard Business School, and holds a BA in Public Policy Studies from Duke University in Durham, North Carolina.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded more than $95 million in research to date, either directly or through partnerships. For more information please visit the Foundation's Web site at

SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Katee Holmes Vs Katie Holmes Case of Losing Virginity
2. Katie Holmes in most Influential Celebs List
3. Wood Appointed As the First Chair of SAADAT
4. Yoga Guru appointed Bihars brand ambassador
5. Disappointed Students Plan To Intensify Agitation Nationwide
6. City Surgeon Appointed Adviser To Armed Forces
7. Indian-American Appointed for US Hospital Top Post
8. Retiring Government Doctors to Be Reappointed to Overcome Paucity of Specialists
9. Bruce Vladeck Will Hold Fort (interim) of UMDNJ
10. Interim WHO Chief Confirms No radical changes in WHO
11. Interim OPD saves the day for patients
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... (PRWEB) , ... November 26, 2015 , ... ... Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and ... Office in Nairobi (UNON) for the opening of the 5th African Network for ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: